N 3 (184) 2023. P. 84–88

OSTEOPOROSIS IN CHRONIC LIVER DISEASE: PATHOGENESIS, DIAGNOSTICS, AND TREATMENT

O. P. Mialiuk, M. I. Marushchak, O. V. Babiak, R. O. Sabadyshyn, V. V. Palapa

Municipal Institution of Higher Education “Rivne Medical Academy” of Rivne Region Council, Rivne, Ukraine
Ivan Horbachevsky Ternopil National Medical University of the Ministry of Health of Ukraine, Ternopil, Ukraine

Osteoporosis is a systemic metabolic disease of the skeleton, characterized by a decrease in bone mass and a violation of the microarchitectonics of bone tissue, which leads to increased fragility and bone fractures. The high social significance of osteoporosis is determined by its consequences – fractures of the vertebrae and bones of the peripheral skeleton, which lead to an increase in morbidity, disability and mortality among the elderly, and therefore to large financial costs of the health care industry. For the timely implementation of preventive measures, risk factors for osteoporosis and fractures are well defined, among which chronic liver diseases occupy a prominent place, as evidenced by the appearance of the term “hepatic osteoporosis (osteodystrophy)”.

The aim of the study. To form a more detailed understanding of the genesis of osteoporosis in chronic liver diseases.

Materials and methods. In the course of the research, the latest scientific sources on the specified issue were analyzed.

Results. The bone system and the mechanisms of its remodeling are largely ignored by hepatologists, despite the obvious damage to bone tissue in hepatitis, cirrhosis of the liver, biliary dysfunction, etc. According to various researchers, osteoporosis is diagnosed in 25–55% of patients with chronic liver disease. The formation of osteopenic syndrome and osteoporosis in liver pathology is multifactorial, and the pathogenetic mechanisms of this process are quite complex and ambiguous. Currently, it is believed that the frequency of osteomalacia in chronic liver disease is exaggerated, and a frequent reaction of bone tissue in chronic hepatitis and liver cirrhosis is osteoporosis. The most rapid and intensive loss of bone mass occurs in autoimmune hepatitis, autoimmune cirrhosis and primary biliary cirrhosis of the liver. To date, the main risk factors for the development of osteoporosis and osteopenic syndrome in chronic liver disease have been identified. It has been established that the formation of hepatogenic osteopathy and osteoporosis is pathogenetically related to the course of chronic hepatitis and cirrhosis of the liver and is an important symptom complex of these diseases. Glucocorticoids (GCs) are the mainstay of treatment for chronic inflammatory diseases and the liver is no exception, so it is important to recognize their negative impact on bone remodeling. They inhibit synthetic osteoblasts, induce their apoptosis, initiate the accumulation of fatty inclusions in hepatocytes, provoking steatohepatitis. Patients who take oral GCs for a long time are at increased risk of developing osteoporosis with significant bone loss in the first months of treatment.

Conclusions. Thus, bone tissue is a target organ in chronic liver disease, targeted by inflammatory aggression and affected by numerous biochemical metabolic and hormonal disorders. Therefore, patients with CLD are at risk of developing secondary osteoporosis.

Key words: osteoporosis, liver cirrhosis, chronic hepatitis, glucocorticoids.

REFERENCES

  1. Vachliotis ID, Anastasilakis AD, Goulas A, Goulis DG, Polyzos SA. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. Diabetes Obes Metab. 2022;24(9):1702-1720. doi:10.1111/dom.14774
  2. Filip R, Radzki RP, Bieńko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging. 2018;13:1879-1891. Published 2018 Oct 4. doi:10.2147/CIA.S170533
  3. Lim WH, Ng CH, Ow ZGW, et al. A systematic review and meta-analysis on the incidence of osteoporosis and fractures after liver transplant. Transpl Int. 2021;34(6):1032-1043. doi:10.1111/tri.13863
  4. Pugliese N, Arcari I, Aghemo A, Lania AG, Lleo A, Mazziotti G. Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges. World J Gastroenterol. 2022;28(14):1430-1443. doi:10.3748/wjg.v28.i14.1430
  5. Guañabens N, Parés A. Osteoporosis en la cirrosis hepática [Osteoporosis in liver cirrhosis]. Gastroenterologia y hepatologia. 2012;35(6):411-420. https://doi.org/10.1016/j.gastrohep.2012.01.017
  6. Yarema N, Kotsiuba O, Krytskyy T, Marushchak M, Krynytska I. Peculiarities of arterial hypertension in postmenopausal women with bone mineral density disorders and dyslipidemia. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2020;48(283):5-9. (In Ukrainian)
  7. Mіalіuk OP, Babyak O., Sabadishin RO, Danilyuk AP, Pasternak AA. Change the indications of lipid peroxidation and antioxidant system in the liver of the eyelids in the case of the Mexidol drug test against aphids, experimental obesity and bronchial asthma. Bulletin of medical and biological records 2021;4:64-68. (In Ukrainian)
  8. Guañabens N, Parés A. Liver and bone. Archives of biochemistry and biophysics. 2010;503(1):84-94. https://doi. org/10.1016/j.abb.2010.05.030
  9. Yang L, Yang CQ. Zhonghua Gan Zang Bing Za Zhi. 2021;29(3):204-208. doi:10.3760/cma.j.cn501113-20210208-00078
  10. Bertoldo F, Cianferotti L, Di Monaco M, et al. Definition, Assessment, and Management of Vitamin D Inadequacy: Suggestions, Recommendations, and Warnings from the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS). 2022;14(19):4148. Published 2022 Oct 6. doi:10.3390/nu14194148
  11. Krynytska I, Marushchak M, Zaets T, Savchenko I, Habor H. Investigation of bone mineralization in patients with coronary heart disease complicated by chronic heart failure, stage ii-a. Georgian medical news. 2017;(267):43-48. (In Ukrainian)
  12. Jeong HM, Kim DJ. Bone Diseases in Patients with Chronic Liver Disease. Int J Mol Sci. 2019;20(17):4270. Published 2019 Aug 31. doi:10.3390/ijms20174270
  13. Yang YJ, Kim DJ. An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia. Int J Mol Sci. 2021;22(5):2604. Published 2021 Mar 5. doi:10.3390/ijms22052604
  14. Rosen CJ. The Epidemiology and Pathogenesis of Osteoporosis. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; June 21. 2020.
  15. Guañabens N, Parés A. Osteoporosis in chronic liver disease. Liver international : official journal of the International Association for the Study of the Liver. 2018;38(5):776-785. https://doi.org/10.1111/liv.13730
  16. Sobh MM, Abdalbary M, Elnagar S, et al. Secondary Osteoporosis and Metabolic Bone Diseases. J Clin Med. 2022;11(9):2382. Published 2022 Apr 24. doi:10.3390/jcm11092382
  17. Hidalgo DF, Boonpheng B, Sikandar S, Nasr L, Hidalgo J. Chronic Liver Disease and the Risk of Osteoporotic Fractures: A Meta-Analysis. 2020;12(9):e10483. Published 2020 Sep 16. doi:10.7759/cureus.10483
  18. Handzlik-Orlik G, Holecki M, Wilczyński K, Duława J. Osteoporosis in liver disease: pathogenesis and management. Ther Adv Endocrinol Metab. 2016;7(3):128-135. doi:10.1177/2042018816641351
  19. Kizilgul M, Ozcelik O, Delibasi T. Bone health and vitamin D status in alcoholic liver disease. Indian J Gastroenterol. 2016;35(4):253-259. doi:10.1007/s12664-016-0652-1
  20. Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol. 2020;8(1):76-86. doi:10.14218/JCTH.2019.00051
  21. Brown JP. Long-Term Treatment of Postmenopausal Osteoporosis. Endocrinol Metab (Seoul). 2021;36(3):544-552. doi:10.3803/EnM.2021.301
  22. Ignatiev A, Turchin N, Ermolenko T, Manasova G, Prutiyan T. Georgian Med News. 2020;(303):93-97.
  23. Guañabens N, Parés A. Management of osteoporosis in liver disease. Clinics and research in hepatology and gastroenterology. 2011;35(6-7):438-445. https://doi.org/10.1016/j.clinre.2011.03.007
  24. Wariaghli G, Mounach A, Achemlal L, et al. Osteoporosis in chronic liver disease: a case-control study. Rheumatol Int. 2010;30(7):893-899. doi:10.1007/s00296-009-1071-8
  25. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46(4):1271-1278. doi:10.1002/hep.21852
  26. Maalouf NM, Sakhaee K. Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients. Curr Treat Options Gastroenterol. 2006;9(6):456-463. doi:10.1007/s11938-006-0002-y
  27. Belizaire R, Wong WJ, Robinette ML, Ebert BL. Clonal haematopoiesis and dysregulation of the immune system [published online ahead of print, 2023 Mar 20]. Nat Rev Immunol. 2023;10.1038/s41577-023-00843-3. doi:10.1038/s41577-023-00843-3
  28. Selmi C, Generali E, Gershwin ME. Rheumatic Manifestations in Autoimmune Liver Disease. Rheum Dis Clin North Am. 2018;44(1):65-87. doi:10.1016/j.rdc.2017.09.008
  29. Irshad M, Gupta P, Irshad K. Immunopathogenesis of Liver Injury During Hepatitis C Virus Infection. Viral Immunol. 2019;32(3):112-120. doi:10.1089/vim.2018.0124
  30. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicol Sci. 2010;115(2):307-321. doi:10.1093/toxsci/kfq009
  31. Stolina M, Guo J, Faggioni R, Brown H, Senaldi G. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol. 2003;109(3):347-354. doi:10.1016/j.clim.2003.09.001
  32. Nasi M, Pinti M, De Biasi S, et al. Aging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV. Immunol Lett. 2014;162(1 Pt B):329-333. doi:10.1016/j.imlet.2014.06.012
View article PDF